...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Need An Explanation

I reduced the price to the absurd for purposes of expounding a point that everyone of the insiders would refuse to do an IPO at a price that a broker would do a bought deal at.

I then carried on with a hypothetical series of mental negotiations done internally to bring out my idea that $1.00 is a price which is reasonable for both Zenith and KD.

I considered 10 cents to be sufficiently absurd to show the resultant mental arguments.

Of course brokers want to make a great deal of money themselves and they do not really do a reasonable price setting knowing the value of the company's IP since they do not know what it is.

Share
New Message
Please login to post a reply